Posted by AGORACOM-JC
at 9:45 AM on Thursday, March 4th, 2021
Announced the appointment Ian Cameron, former General Manager of Global Brand & Marketing Communications at Seiko Epson Corporation, as its VP of Marketing, effective March 15th, 2021
Ian Cameron is a global marketing, eCommerce, and brand executive with over 20 years of experience delivering positive business results for major companies, including Epson, a global printing equipment leader with a market cap of $US 5.73 billion
VANCOUVER, British Columbia, March 04, 2021 – Loop Insights Inc. (MTRX:TSXV RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing for the brick and mortar space, is pleased to announce the Company has appointed Ian Cameron, former General Manager of Global Brand & Marketing Communications at Seiko Epson Corporation, as its VP of Marketing, effective March 15th, 2021.
Cameron Joins Loop Insights After Establishing and Managing Epson’s Global Marketing Team
Ian Cameron is a global marketing, eCommerce, and brand executive with over 20 years of experience delivering positive business results for major companies, including Epson, a global printing equipment leader with a market cap of $US 5.73 billion.
Epson (an abbreviation for “Son of Electronic Printer”), is a Japanese electronics company and one of the world’s largest manufacturers of computer printers, and information and imaging-related equipment.
Loop Insights CEO Rob Anson stated: “Ian’s experience working with a global leader such as Epson speaks to the level of talent that Loop has been able to attract. As a global marketing and communications expert, Ian is another key strategic addition to our team. I look forward to working alongside Ian and witnessing his impact on our marketing efforts as Loop continues to position and prove itself as a global leader in the Artificial Intelligence and data applications space.”
Strong Executive Leadership Positions Loop to Continue to Accelerate Expansion for 2021
Under Cameron’s leadership, Epson centralized redundant regional activities increasing profitability significantly and improved their global digital user experience while saving millions of dollars annually for the company through a Global digital transformation project that unified multiple disparate regional content management, eCommerce, and product information systems.
Cameron’s experience in driving successful enterprise global marketing campaigns is expected to significantly contribute to continued growth and scale for Loop Insights in 2021.
Ian Cameron stated: “I am very excited to join the Loop team and to support and contribute to the growth of the company. Loop’s clear multifaceted value propositions are very exciting and as a marketing professional, the value of attribution, campaign performance, and the granularity of the data analytics that Loop is able to provide is simply unparalleled. Loop’s technology is something that marketers only wish for and dream of.”
On January 28th , Loop Insights appointed Tamer Shafik, the former Director of Solution Architecture at NTT Data Corp of Japan, as the company’s new Chief Technology Officer in support of Loop’s global scale. Shafik joined the company as a result of a flourishing partnership between Loop and NTT Data. Shafik’s immense experience and skillset have already made a significant impact with the Loop team, transforming the product department in a short amount of time.
Posted by AGORACOM-JC
at 5:50 PM on Wednesday, March 3rd, 2021
AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.
Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.
Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.
Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make. Moreover, he serves as an advisor to several small cap companies.
If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.
On today’s episode we discuss the outlook for esports, why it is so explosive and a few small cap esports companies to consider including:
Esports Entertainment Group (GMBL:NASDAQ)
FansUnite Entertainment (FANS:CSE / FUNFF:OTCQB)
TGS Esports (TGS:TSXV)
…. and newcomer Intema Solutions (ITM:TSXV) Who recently completed their acquisition of HypeX
Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.
Posted by AGORACOM-JC
at 5:01 PM on Wednesday, March 3rd, 2021
Quizam Media Corp’s (QQ:CSE QQQFF:OTC) wholly owned subsidiary Quantum 1 Cannabis is experiencing rapid growth across British Columbia!
In the past 12 months, Quantum 1 has opened stores in:
North Vancouver
Vernon
Grand Forks
Keremeos
Creston
And it will soon be opening its sixth, and flagship, store in Oakridge, B.C.
In Tandem with this expansion, quarterly revenue is accelerating rapidly, rising from $138,000 in Nov 2019 to $954,000 in Nov 2020.
What’s its secret sauce? The company places a huge emphasis on education. That’s because Quizam has its roots as an educational media company that spent a long time educating people about cannabis, long before it became legal.
In this nascent market, people are looking for trusted, authoritative voices
The company’s growth comes as Canada is experiencing ‘The Great Cannabis Gold Rush’ –
By 2021, Canada’s cannabis market is expected to reach $3bn, translating to 77.9% CAGR from 2018-2021.
Cannabis now contributes $14.6bn to Canada’s economy, up from $8bn previous est.
Cannabis 2.0 new products (candy, drinks) could generate $2.5bn in sales in Canada.
You’re going to want to get comfy for this conversation with Russ Rossi, Quizam Media’s President & CEO:
Posted by AGORACOM-JC
at 9:32 AM on Tuesday, March 2nd, 2021
Announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa
He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.
Mr. Karam holds a master’s degree in Biomedical Engineering from the University of Surrey in the United Kingdom. He brings 20 plus years of experience in the health care industry, where he has held several leading roles within multinational companies covering Central and Eastern Europe, Turkey, the Middle East, Africa and Pakistan markets. He has a career history with Medtronic, Molnlycke, Stryker, and several other global companies.
“Mr. Karam’s strong experience and skills will be of high added value to our overall strategy in the region, as he helps develop the EMEA region with a specific focus on Turkey, the Middle East and African sub-regions. Mr. Karam will play an integral part in accelerating MedX’s revenue growth prospects by activating his already well-established medical device distributors network to the benefit of MedX’s skin assessment telemedicine technology in the region,” said Mr. Naman Demaghlatrous, Managing Director for EMEA.
Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa. He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.
“We are pleased to welcome Paul to the MedX team. We are fortunate to attract a person of his calibre, and I think it speaks to the strength of our offering and the opportunity it presents in the EMEA market,” stated Michael Druhan, President of Dermatological Services & Products.
Posted by AGORACOM
at 9:20 AM on Tuesday, March 2nd, 2021
Highlights:
Rhodium (Rh) is the most valuable platinum group metal (PGM), with recent spot price highs of over $US24,000/oz Rh, nearly 18 times higher than Pt
303 Rh assay results reported for the Pine Zone of the River Valley Deposit
Highest assay result is 0.177 g/t Rh, with 9 other samples returned assays at or greater than 0.100 g/t Rh and a total of 50 samples returned assays higher than 0.050 g/t Rh
The highest Rh concentrations coincide with the highest palladium (Pd) and platinum (Pt) grades – Rh concentrations in the River Valley Deposit are equivalent to 12% of the Pt grades
Based on encouraging results from phase 1, subsequent phases of the multi-phase Rh evaluation program will take samples of PGM mineralized intervals from the Dana South and Lismer zones
The River Valley Deposit is one of North Americas largest undeveloped primary platinum-group metal projects with 2.867 Moz Palladium Equivalent (PdEq) in the Measured + Indicated classifications and 1.059 Moz Pd Eq in the Inferred classification
New Age Metals Inc. (NAM) (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) (“NAM” or the “Company”) announces completion of Phase 1 of an ongoing Rh assay program on the River Valley Palladium Deposit near Sudbury, Ontario (Figure 1). Phase 1 of the Rh assay program collected 303 pulp samples from 17 mineralized intervals in 14 drill holes through the Pine Zone. The samples were selected to provide Rh data for mineralization in two cross-sections spaced 50 metres apart through the Pine Zone, located near the north end of the 16 km long River Valley Deposit (Figure 1). In addition to Rh, the samples were also assayed for gold (Au), iridium (Ir), palladium (Pd), platinum (Pt), and ruthenium (Ru). The assays were completed on 2015-2020 drill core sample pulps at the Geoscience Laboratories in Sudbury.
Posted by AGORACOM-JC
at 4:17 PM on Monday, March 1st, 2021
Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.
In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.
Now the firm has appointed Patrick O’Donnell to its board of directors.
O’Donnell comes with significant company-building experience
He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing
Claude LeDuc, Ortho’s CEO, breaks down the appointment:
Posted by AGORACOM
at 8:38 AM on Friday, February 26th, 2021
New Age Metals Inc. (TSXV:NAM) (OTC:NMTLF) (FSE:P7J) (“NAM” or the “Company“), is pleased to announce that, due to strong investor demand, it has increased its previously announced non-brokered private placement offering (the “Private Placement”) to up to $5,250,000, consisting of: (i) up to $3,500,000 in units of the Company (the “Units”) at a price of $0.16 per Unit and (ii) up to $1,750,000 in flow-through units of the Company (the “FT Units”) at a price of $0.20 per FT Unit.
Each Unit shall be comprised of one common share (a “Common Share“) of the Company and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one additional Common Share at an exercise price equal to $0.20 at any time up to 24 months from closing of the Private Placement.
Each FT Unit will consist of one common share of the Company that will qualify as a “flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (“FT Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “FT Unit Warrant”). Each FT Unit Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price equal to $0.25 at any time up to 24 months closing of the Private Placement.
The Company intends to use the net proceeds from the sale of Units towards its exploration and development work on its projects. The primary use of proceeds from this financing will be for the completion of a Prefeasibility Study for the Company’s flagship River Valley Platinum Group Metals (PGM) Project, one of North America’s largest undeveloped primary palladium projects, and for general corporate and working capital purposes. The Company intends to use the net proceeds from the sale of FT Units towards its exploration work on both the Company’s PGM and Lithium divisions. This will include a maiden drill program on the Company’s Lithium Two Project in Manitoba and continued drilling at River Valley.
Posted by AGORACOM-JC
at 9:11 AM on Thursday, February 25th, 2021
Closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes
Each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.
Full Details of each of the Closings are as follows:
First Closing on January 27, 2021: $2 million, with cash commissions of $114,000 and issuance of 300,000 Broker Warrants;
Second Closing on January 28, 2021: $500,000, with cash commissions of $15,000 and issuance of 107,143 Brokers Warrants;
Third Closing on February 3, 2021: $100,000, with no cash commissions and no Brokers Warrants;
Fourth, and final Closing, on February 23, 2021: $1.4 million, with cash commissions of $81,000 and issuance of 578,576 Brokers Warrants.
The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of 4 months and one day from the respective dates of issuance. Qualified Agents received commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. A total of $210,000 of cash commissions were paid, and 985,719 Agent’s Warrants have been issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.
MedX’s CEO, Rob von der Porten stated, “We believe this financing clearly demonstrates a vote of confidence in our strategic direction and ability to be a leader in the teledermatology space. This funding is significant to furthering the development of our sales initiatives and advancing MedX’s Dermsecure TM platform to a wider global network.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Posted by AGORACOM-JC
at 8:01 AM on Thursday, February 25th, 2021
Launch Confirms Empower Stated Strategy To Execute National Clinic Expansion Following Canadian Clinics Acquisition And Partnership Announcements in 2021
Announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue.
Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.
VANCOUVER, BC / February 25, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue. Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.
THREE ONTARIO LOCATIONS AND TWELVE PHYSICIANS COMMITTED TO OPEN
The locations and approximate sizes of the integrated health centres are as follows:
1) Etobicoke, Ontario Approximately 2,700 sq ft.
2) London, Ontario Approximately 3,100 sq ft.
3) Etobicoke, ON (site two) Approximately 2,900 sq ft.
“Dr. Aviv Tsimmerman and Dr. Jordan Rabinowitz are executing on our growth initiatives, they are achieving milestones, they are opening our healthcare centers.” said Steven McAuley, Chairman & CEO. “Our approach is based on patients and their needs, the delivery of care, an improved healthcare model, that provides advanced technology and access for an improved healthcare outcome.”
Each location is expected to host 4-6 physicians. Empower has already secured commitments from twelve (12) physicians to date, with numerous additional medical doctors and para-medical practitioners expressing interest to join the team.
“Having a strategic blend of health professionals allows us to provide an unparalleled integrative healthcare experience.” stated Dr. Jordan Rabinowitz, Chief Operating Officer. He further states, “This defines our path to assist millions of Canadians nationwide.”
HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUE MODEL
Empower will be opening primary care, plus para-medical healthcare services, with a target of four (4) to six (6) medical doctors and four (4) to six (6) paramedical practitioners per location.
Primary care services include:
Family physicians
Walk-in physicians
Tele-medicine and virtual care
Empower expects to generate $400,000 – $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 – $2,400,000 annually per location.
Paramedical services include:
Chiropractic
Physiotherapy
Registered Massage Therapy
Chiropody
Acupuncturists
Osteopaths
Nutritionists
Empower expects to generate $960,000 – $1,200,000 in annual revenue per location.
Together, when each location is fully operational, Empower expects to generate $2,560,000 – $3,600,000 in annual revenue per location.
ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED
Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:
Dermatology
Cardiology
Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
